ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of Nick Maishman as Chief Operating Officer (“COO”).
ViroCell, an innovation-driven Contract Development and Manufacturing Organisation (“CDMO”), is today addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.
ViroCell Biologics, founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of Nick Maishman as Chief Operating Officer (COO).
ViroCell, an innovation-driven Contract Development and Manufacturing Organisation, is today addressing the global viral vector supply-demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene-modified cells for clinical trials. ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies.
Read More